NSCLC患者Tα1维持治疗与T、B、NK细胞免疫功能联合测定的临床研究  

The Clinical Sdudy of NSCLC Patients with The Maintenance Treatment of Thymopeptides α1(Tα1) and Combined Determination of The Immune Function of The T,B and NK Cells

作　　者：王亚兰[1] 巴彩霞[1] 杨永岩[1] 李杰[1] 孟令茹[1] 于焕欣 

机构地区：[1]包头市肿瘤医院肿瘤内科,内蒙古包头014030

出　　处：《疾病监测与控制》2012年第1期9-11,共3页Journal of Diseases Monitor and Control

摘　　要：目的研究NSCLC患者Tα1维持治疗与T、B、NK细胞免疫功能联合测定的临床意义,方法对60例非小细胞肺癌(NSCLC)患者化疗后,随机分为两组,维持组30例给予胸腺肽α1(Tα1)维持治疗3～6个月,1.6mg,每周两次,对照组30例只给予观察;所有患者治疗前及治疗后分别测定CD3/HLA-DR,CD4/HLA-DR/CD8,CD3/CD16+CD56,CD25/CD3/CD19,对比用Tα1维持组与非Tα1维持组两组的PFS(无进展生存期),中位生存期(MST),生活质量(KPS评分)。总生存时间(OS)。结果本组患者化疗前后细胞免疫功能表明;化疗后CD3^+、CD4^+细胞升高,CD8^+细胞下降,但与化疗前无明显差异(P>0.05)。CD4^+/CD8^+则显著升高,NK细胞降低,B淋巴细胞增高,与化疗前均有统计学意义(P<0.05)。胸腺肽α1治疗组(A组)和对照组(B组)治疗后CD3^+、CD4^+、CD4^+/CD8^+、B NK细胞活性值均提高,P<0.05,CD8值无明显变化。细胞免疫功能与临床参数的关系,Ⅲb期与Ⅳ期相比较P<0.05,≤55岁组与>55岁组比较P<0.05,可见临床分期越晚,年龄越大细胞免疫功能越低下。Tα1维持治疗组近期有效率(CR,PR及ORR)及PFS,MST,与对照组相比均有统计学意义(P<0.05),1年0S两组没有统计学意义,P>0.05。两组3,4度毒副反应没有明显差异,治疗组较对照组明显提高KPS,18比5,体重也增加,17比6,P<0.01有显著的统计学差异。结论胸腺肽α维持治疗可使晚期非小细胞肺癌患者化疗后的免疫功能提高,增强抗病能力,减弱抑制肿瘤的能力,延长生存时间,毒副反应轻,生活质量提高,值得进一步研究推广。Objective To observe the clinical significance of NSCLC patients with the maintenance treatment of Thymopeptidesα1（Tα1） and combined determination of the immune function of the T,B and NK cells.Methods Sixty NSCLC patients of postchemotherapy were randomly cultured two groups, maintain group of 30 cases were Thymopeptidesα1（Tα1） maintenance treatment 3 to 6 months,1.6 mg,twice a week,and the control group of 30 cases were only to watch.All patients were measured CD3/HLA-DR,CD4/HLA-DR/CD8,CD3/CD16~＋,CD56,CD25/CD3/CD19 before and after treatment and compared the two groups with PFS（progression-free surial）,median survival（MST）,quality of life（KPS score）,Overall survival time（OS） of Tal keep group and without Tal maintain group.Results The cellular immune function of all patients before and after chemotherapy shows that chemotherapy eleved CD3~＋,CD4~＋,and decreased CD8~＋,but no obvious difference with chemotherapy before（P0.05）.Chemotherapy significantly increased CD4~＋/ CD8~＋ and the B lymphocytes,while NK cells were reduced,and have statistical significance（P0.05）.The CD3~＋,CD4~＋,CD4~＋/ CD8~＋,B lymphocytes and NK cells were incresed（P0.05） in Tal treatment group（group A） and the control group（group B） after treatment,while CD8 remained unchanged.The Cellular immune function ofⅢb period compared withⅣperiod（P0.05）,and lower than 55 years old group compared with more than 55 years old group（P0.05）,the relationship of the Cellular immune function and the clinical parameters shows that the later clinical stage or the older the lower cellular immune function.The recent efficient（CR,PR and ORR） and PFS,MST of Tal maintenance treatment group have statistically significant compared with the control group（P0.05）, but OS of 1 year was not statistically significant in two groups（P0.05）.The two groups of three,four degrees of adverse reaction have no significant difference in the treatment group and the control group,while the KPS（18

关 键 词：非小细胞肺癌 细胞免疫功能 维持治疗 胸腺肽Α1 

分 类 号：R730.5[医药卫生—肿瘤]